• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Veramark Technologies

Veramark Technologies

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

    FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

  2. Our Outlook for Consumer Cyclical Stocks

    The U.S. economy is in decent shape, but we are being even more selective given recent outperformance.

  3. Our Outlook for Consumer Cyclical Stocks

    As macro headwinds mount, we would look for a larger valuation discount among consumer cyclical names.

  4. Our Outlook for the Market

    As the risk of increasing inflation looms, the risk/reward opportunity in stocks does not signal a screaming buy to us at this point.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.